Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease

Cerebrospinal fluid-induced retardation of amyloid β aggregation correlates with Alzheimer's disease and the APOE ε4 allele

(2016) E.R. Padayachee et al.   BRAIN RESEARCH

The Cellular Phase of Alzheimer’s Disease

(2016) Bart De Strooper et al.   CELL

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A 42 aggregates linked with Alzheimers disease

(2016) J. Habchi et al.   Science Advances

A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers

(2015) Samuel I A Cohen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers

(2015) Samuel I A Cohen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

(2014) Eric Karran et al.   ANNALS OF NEUROLOGY

The amyloid state and its association with protein misfolding diseases

(2014) Tuomas P. J. Knowles et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Chemical kinetics for drug discovery to combat protein aggregation diseases

(2014) Paolo Arosio et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Quantification of the Concentration of Aβ42 Propagons during the Lag Phase by an Amyloid Chain Reaction Assay

(2013) Paolo Arosio et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Natural Compounds May Open New Routes to Treatment of Amyloid Diseases

(2013) Jan Bieschke   Neurotherapeutics

Proliferation of amyloid- 42 aggregates occurs through a secondary nucleation mechanism

(2013) S. I. A. Cohen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

2012 Alzheimer’s disease facts and figures

(2012)   Alzheimers & Dementia

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

Alzheimer Mechanisms and Therapeutic Strategies

(2012) Yadong Huang et al.   CELL

Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators

(2012) Albane le Maire et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

From Macroscopic Measurements to Microscopic Mechanisms of Protein Aggregation

(2012) Samuel I.A. Cohen et al.   JOURNAL OF MOLECULAR BIOLOGY

Utility of an improved model of amyloid-beta (Aβ1-42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease

(2012) Gawain McColl et al.   Molecular Neurodegeneration

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Modulation of RXR function through ligand design

(2011) Efrén Pérez et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Alzheimer's Disease: The Challenge of the Second Century

(2011) D. M. Holtzman et al.   Science Translational Medicine

Small Molecule Microarrays Enable the Discovery of Compounds That Bind the Alzheimer’s Aβ Peptide and Reduce its Cytotoxicity

(2010) Jermont Chen et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Amyloid β-Protein Aggregation Produces Highly Reproducible Kinetic Data and Occurs by a Two-Phase Process

(2009) Erik Hellstrand et al.   ACS Chemical Neuroscience